Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CPA3 | P15088 | 1/20 | 0.36 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.35 |
| ▸ | ALPI | P09923 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | XIAP | P98170 | 1/20 | 0.35 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4510553 | 1.00 | MEN1 (0.39) | MEN1KMT2AALDH1A1LMNAHPGD | |
| SCHEMBL2176148 | 1.00 | MEN1 (0.39) | MEN1KMT2AALDH1A1LMNAHPGD | |
| SCHEMBL4221112 | 1.00 | MEN1 (0.39) | MEN1KMT2AALDH1A1LMNAHPGD | |
| SCHEMBL464737 | 0.89 | MAOB (0.47) | L3MBTL1PTGS1 | |
| SCHEMBL970613 | 0.87 | TAS2R14 (0.37) | KMT2AALDH1A1HTTNPC1RAB9A | |
| SCHEMBL5391773 | 0.86 | NAPRT (0.43) | KMT2AALDH1A1LMNAHTTCYP1A2 | |
| SCHEMBL5391766 | 0.86 | NAPRT (0.43) | KMT2AALDH1A1LMNAHTTCYP1A2 | |
| SCHEMBL5221314 | 0.83 | MME (0.39) | PTGS1 | |
| SCHEMBL5221308 | 0.83 | MME (0.39) | PTGS1 | |
| SCHEMBL4891373 | 0.83 | BACE1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013011485-A1 | PROCESS FOR THE PREPARATION OF SULFONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2013-01-24 | — | — | WO | disclosed |
| US-8350048-B2 | Amide compounds as boosters of antivirals | JANSSEN R&D IRELAND (IE) | 2013-01-08 | — | — | US | disclosed |
| US-8163766-B2 | Beta-secretase modulators and methods of use | AMGEN INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20120053200-A1 | BACE 2 INHIBITORS | HOFFMANN-LA ROCHE INC. | 2012-03-01 | — | — | US | disclosed |
| US-20110257111-A1 | Hydroxyethlamino Sulfonamide Derivatives | CONCERT PHARMACEUTICALS, INC. | 2011-10-20 | — | — | US | disclosed |
| US-20110224443-A1 | PREPARATION OF FOSAMPRENAVIR CALCIUM | DR. REDDY'S LABORATORIES LIMITED (IN) | 2011-09-15 | — | — | US | disclosed |
| US-7973047-B2 | Beta-Secretase modulators and methods of use | AMGEN INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-20110118250-A1 | BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2011-05-19 | — | — | US | disclosed |
| US-7897635-B2 | HIV protease inhibitors | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2011-03-01 | — | — | US | disclosed |
| US-7872009-B2 | Beta-Secretase modulators and methods of use | AMGEN INC. (US) | 2011-01-18 | — | — | US | disclosed |
| US-20060052615-A1 | Phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer's disease | MERCK SHARP & DOHME LLC | 2006-03-09 | — | — | US | disclosed |
| EP-1562897-A1 | PHENYLCARBOXAMIDE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER S DISEASE | Merck & Co., Inc. (US) | 2005-08-17 | — | — | EP | disclosed |
| US-20050148623-A1 | Prevent reproduct of aids virus | ABBVIE INC. | 2005-07-07 | — | — | US | disclosed |
| US-20050131017-A1 | HIV protease inhibiting compounds | ABBOTT LABORATORIES | 2005-06-16 | — | — | US | disclosed |
| US-20040175782-A1 | Biotransformation of compounds using non-prokaryotic microalgae | TETHYS RESEARCH LLC | 2004-09-09 | — | — | US | disclosed |
| WO-2004043916-A1 | PHENYLCARBOXAMIDE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK & CO., INC. (US) | 2004-05-27 | — | — | WO | disclosed |
| US-20040097594-A1 | Sulfonamide inhibitors of aspartyl protease | HALE MICHAEL ROBIN (US) | 2004-05-20 | — | — | US | disclosed |
| US-20040039016-A1 | HIV protease inhibitors | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-02-26 | — | — | US | disclosed |
| US-6613743-B2 | Administering to a patient suffering from viral infections a sulfonamides antiviral agents which are aspartyl protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-09-02 | — | — | US | disclosed |
| US-20020049201-A1 | Sulfonamide inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED | 2002-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097594-A1 | Sulfonamide inhibitors of aspartyl protease | SPINT2, PRSS1, DNPEP | MEN1 4380/4885KMT2A 860/4885ALDH1A1 1841/4885 |
| US-20050148623-A1 | Prevent reproduct of aids virus | SERPINB1, PRSS1, SERPINA3 | MEN1 2754/4885KMT2A 2273/4885ALDH1A1 1209/4885 |
| US-20020049201-A1 | Sulfonamide inhibitors of aspartyl protease | SPINT2, PRSS1, DNPEP | MEN1 4380/4885KMT2A 860/4885ALDH1A1 1841/4885 |
| US-20110118250-A1 | BETA-SECRETASE MODULATORS AND METHODS OF USE | BACE1, BACE2, APP | MEN1 3013/4885KMT2A 3113/4885ALDH1A1 2087/4885 |
| US-20060052615-A1 | Phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer's disease | BACE1, BACE2, PSEN1 | MEN1 3655/4885KMT2A 3010/4885ALDH1A1 1594/4885 |
| US-20120053200-A1 | BACE 2 INHIBITORS | BACE2, BACE1, PSEN2 | MEN1 3688/4885KMT2A 1407/4885ALDH1A1 756/4885 |
| US-20050131017-A1 | HIV protease inhibiting compounds | SERPINB1, HPN, DNPEP | MEN1 4515/4885KMT2A 4151/4885ALDH1A1 2920/4885 |
| US-20040039016-A1 | HIV protease inhibitors | SERPINB1, TMPRSS15, DNPEP | MEN1 4738/4885KMT2A 3671/4885ALDH1A1 2558/4885 |
| US-20110257111-A1 | Hydroxyethlamino Sulfonamide Derivatives | HTRA1, PRSS8, PRSS1 | MEN1 3920/4885KMT2A 662/4885ALDH1A1 824/4885 |
| US-20110224443-A1 | PREPARATION OF FOSAMPRENAVIR CALCIUM | ORAI1, CACNA1I, FOS | MEN1 845/4885KMT2A 3315/4885ALDH1A1 3907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.